Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome.
OBJECTIVE
To determine the efficacy of IV albumin in the prevention of severe ovarian hyperstimulation syndrome (OHSS).


METHODS
Prospective study group with historical control.


METHODS
University hospital-based IVF program.


METHODS
Between 1993 and 1995, 42 consecutive patients undergoing IVF-ET or tubal ET who had serum E2 levels > or = 3,600 pg/mL (conversion factor to SI unit, 3.671) on the day of hCG administration and/or > or = 20 oocytes retrieved were considered at high risk for severe OHSS and were selected as the control group. From December 1995 to October 1996, IV albumin was given to 30 consecutive patients who fulfilled these criteria.


METHODS
The treatment group received IV albumin after oocyte retrieval.


METHODS
Occurrence of severe OHSS.


RESULTS
None of the 16 patients in the treatment group in nonconception cycles developed severe OHSS, compared with 5 (21.7%) of 23 in the control group. In conception cycles, 4 (28.6%) of 14 patients in the treatment group developed severe OHSS, compared with 9 (47.4%) of 19 in the control group. All 4 patients with multiple pregnancies in the treatment group developed severe OHSS, compared with 3 (60%) of 5 in the control group. None of the 10 patients with singleton pregnancies in the treatment group developed severe OHSS, compared with 6 (42.9%) of 14 in the control group.


CONCLUSIONS
Intravenous albumin prevents severe OHSS in high-risk patients who did not conceive or who carried singleton pregnancies, but not in the patients with high-order pregnancies.
Chen
C D
CD
Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei.
Wu
M Y
MY
Yang
J H
JH
Chen
S U
SU
Ho
H N
HN
Yang
Y S
YS
D000328:Adult; D000418:Albumins / Q000008:administration & dosage / Q000627:therapeutic use*; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000627:therapeutic use; D004624:Embryo Transfer; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D008596:Menotropins / Q000008:administration & dosage / Q000627:therapeutic use; D016471:Ovarian Hyperstimulation Syndrome / Q000517:prevention & control*; D011085:Polycystic Ovary Syndrome / Q000150:complications; D011247:Pregnancy; D011272:Pregnancy, Multiple; D011446:Prospective Studies; D012307:Risk Factors
D000418:Albumins; D006063:Chorionic Gonadotropin; D004958:Estradiol; D008596:Menotropins